These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35790236)

  • 21. On peginesatide and anemia treatment in CKD.
    Parfrey PS; Warden G; Barrett BJ
    Am J Kidney Dis; 2013 Oct; 62(4):659-61. PubMed ID: 23810692
    [No Abstract]   [Full Text] [Related]  

  • 22. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
    Singh AK; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Perkovic V; Solomon S; Wanner C; Waikar SS; Wheeler DC; Wiecek A
    Nephrol Dial Transplant; 2022 Apr; 37(5):960-972. PubMed ID: 33744933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Predictors of response to the CERA in chronic hemodialysis treatment-naive by erythropoiesis-stimulating agent].
    Ezziani M; Najdi A; Mikou S; Hanin H; Arrayhani M; Houssaini TS
    Pan Afr Med J; 2015; 20():331. PubMed ID: 26175821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia management in chronic kidney disease: bursting the hemoglobin bubble.
    Weiner DE; Miskulin DC
    Ann Intern Med; 2010 Jul; 153(1):53-5. PubMed ID: 20439567
    [No Abstract]   [Full Text] [Related]  

  • 27. Erythropoiesis-stimulating agents--time for a reevaluation.
    Unger EF; Thompson AM; Blank MJ; Temple R
    N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.
    Suzuki M; Hada Y; Akaishi M; Hiroe M; Aonuma K; Tsubakihara Y; Akizawa T
    Int Heart J; 2012; 53(4):238-43. PubMed ID: 22878802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anemia and iron deficiency - treatment options in chronic kidney disease and in chronic heart failure].
    Emrich IE; Böhm M; Heine GH
    Dtsch Med Wochenschr; 2020 Dec; 145(24):1775-1780. PubMed ID: 33254253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA;
    N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
    [No Abstract]   [Full Text] [Related]  

  • 31. Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD.
    Locatelli F; Del Vecchio L
    Kidney Int; 2023 Jun; 103(6):1025-1027. PubMed ID: 37210194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anemia management in dialysis patients: a PIVOT and a new path?
    Nair S; Trivedi M
    Curr Opin Nephrol Hypertens; 2020 May; 29(3):351-355. PubMed ID: 32235274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
    Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
    Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
    Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anemia of chronic kidney disease: Treat it, but not too aggressively.
    Nakhoul G; Simon JF
    Cleve Clin J Med; 2016 Aug; 83(8):613-24. PubMed ID: 27505883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anemia treatment in patients with chronic kidney disease.
    Drüeke TB
    N Engl J Med; 2013 Jan; 368(4):387-9. PubMed ID: 23343068
    [No Abstract]   [Full Text] [Related]  

  • 38. Forewarned is forearmed: erythropoietin use in CKD patients with cancer.
    Kessler SJ; Bennett CL
    J Nephrol; 2013; 26(5):805-6. PubMed ID: 24052466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
    Hasegawa T; Koiwa F; Akizawa T
    Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.